An echocardiographic sub-study [166] demonstrated that mavacamten led to a significantly higher rate of complete resolution of systolic anterior motion and mitral regurgitation (MR) compared to placebo, with strong correlations between serum NT-proBNP level reduction and echocardiographic parameters. This evidence concerns the gene NPPB and mitral valve insufficiency.